A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point?

Veronica Villani, Alessandra Fabi, Antonio Tanzilli, Francesco Pasqualetti, Giuseppe Lombardi, Antonello Vidiri, Alessandra Gonnelli, Alessandro Molinari, Martina Cantarella, Luisa Bellu, Irene Terrenato, Mariantonia Carosi, Marta Maschio, Stefano Maria Telera, Carmine Maria Carapella, Francesco Cognetti, Fabiola Paiar, Vittorina Zagonel, Andrea Pace

Research output: Contribution to journalArticle

Abstract

Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients & methods: The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months. Results: We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB. Conclusion: The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.
Original languageEnglish
Pages (from-to)1717-1727
Number of pages11
JournalFuture Oncology
Volume15
Issue number15
DOIs
Publication statusPublished - May 1 2019

    Fingerprint

Keywords

  • bevacizumab
  • clinical benefit
  • glioma

Cite this